The second dimension of Guanxinning Injection segmentation addresses product types, which determine formulation stability, administration logistics, and price tiering. The market is principally divided into three categories: lyophilized powder for reconstitution, ready‑to‑use aqueous solution, and prefilled syringe. Lyophilized powder accounts for roughly 55 % of volume because its extended shelf life and cold‑chain flexibility suit regional distributors and hospital pharmacies in emerging markets. Aqueous solution represents about 30 % and is favored in high‑throughput infusion centers where rapid preparation reduces nursing workload, albeit at the cost of stricter temperature control. Prefilled syringe—comprising the remaining 15 %—targets specialty clinics and outpatient settings, offering dose‑accuracy and reduced contamination risk, which commands a premium price. Each type contributes distinct cost structures: raw material sourcing, lyophilization equipment, aseptic filling lines, and packaging. Consequently, the aggregate market size reflects the weighted sum of these type‑specific revenue streams, with formulation choice driven by clinical protocol requirements, regulatory pathways, and payer reimbursement policies.
